JP2024523506A5 - - Google Patents

Info

Publication number
JP2024523506A5
JP2024523506A5 JP2023579154A JP2023579154A JP2024523506A5 JP 2024523506 A5 JP2024523506 A5 JP 2024523506A5 JP 2023579154 A JP2023579154 A JP 2023579154A JP 2023579154 A JP2023579154 A JP 2023579154A JP 2024523506 A5 JP2024523506 A5 JP 2024523506A5
Authority
JP
Japan
Prior art keywords
compound
diffraction pattern
ray powder
powder diffraction
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523506A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034550 external-priority patent/WO2022271846A1/en
Publication of JP2024523506A publication Critical patent/JP2024523506A/ja
Publication of JP2024523506A5 publication Critical patent/JP2024523506A5/ja
Pending legal-status Critical Current

Links

JP2023579154A 2021-06-23 2022-06-22 上皮成長因子受容体阻害剤の塩及び結晶形態 Pending JP2024523506A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214089P 2021-06-23 2021-06-23
US63/214,089 2021-06-23
PCT/US2022/034550 WO2022271846A1 (en) 2021-06-23 2022-06-22 Salt and crystal forms of an epidermal growth factor receptor inhibitor

Publications (2)

Publication Number Publication Date
JP2024523506A JP2024523506A (ja) 2024-06-28
JP2024523506A5 true JP2024523506A5 (https=) 2025-06-30

Family

ID=82608408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579154A Pending JP2024523506A (ja) 2021-06-23 2022-06-22 上皮成長因子受容体阻害剤の塩及び結晶形態

Country Status (9)

Country Link
US (1) US20240293404A1 (https=)
EP (1) EP4359400B1 (https=)
JP (1) JP2024523506A (https=)
CN (1) CN117836287A (https=)
CA (1) CA3223859A1 (https=)
ES (1) ES3042447T3 (https=)
IL (1) IL309469A (https=)
TW (1) TW202317543A (https=)
WO (1) WO2022271846A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4358942A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
CN116554150B (zh) * 2022-12-30 2025-12-19 苏州浦合医药科技有限公司 第四代egfr抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726968B (zh) * 2016-01-07 2021-05-11 開曼群島商Cs醫藥技術公司 Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
MX2022007969A (es) * 2019-12-23 2022-12-13 Blueprint Medicines Corp Inhibidores de egfr.
US20240058340A1 (en) * 2020-09-21 2024-02-22 The Regents Of The University Of California Compositions and methods for treating cancer
EP4358942A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
AR126196A1 (es) * 2021-06-23 2023-09-27 Blueprint Medicines Corp Proceso para preparar inhibidores de egfr

Similar Documents

Publication Publication Date Title
JP2024523506A5 (https=)
TWI619694B (zh) 用於製備喹啉衍生物之方法
CN105209437B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
JP2020517611A5 (https=)
CN1227233C (zh) 纯晶形的5-氯-3-(4-甲磺酰基苯基)-6′-甲基-[2,3′]联吡啶及其合成方法
KR102142796B1 (ko) 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도
US9630952B2 (en) Crystalline forms of afatinib di-maleate
JP2008543974A (ja) ペメトレキセド二酸の結晶形およびその調製方法
JP2003523334A (ja) 7−[4−(4−フルオロフェニル)−6−イソプロピル−2−[メチル(メチルスルホニル)アミノ]ピリミジン−5−イル]−(3r,5s)−3,5−ジヒドロキシ−6−ヘプテン酸の結晶性塩
TW201736383A (zh) 2-[(2s)-1-氮雜雙環[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物之晶形
WO2016054959A1 (zh) 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法
JP2021522335A5 (https=)
WO2023174400A1 (zh) 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用
CN111825700A (zh) 一种吡嗪并噻唑类化合物、其应用及含其的药物组合物
CN112119074A (zh) Egfr抑制剂
JP4904561B2 (ja) アザビシクロオクタン−3−オン誘導体及びその使用
JP2021529175A5 (https=)
TWI551603B (zh) 培美曲塞二酸之晶型及其製備方法
JP6594333B2 (ja) Hx塩の形態の(e)−4−n,n−ジアルキルアミノクロトン酸の製造方法、およびegfrチロシンキナーゼ阻害剤の合成のためのその使用
CN108419436B (zh) 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
JP2022531571A (ja) ジアミノピリミジン化合物の塩、及びその固体形態、その調製方法及びその使用
CN102272126B (zh) 光学纯喹唑啉类化合物
JP6871255B2 (ja) ゲフィチニブの結晶形aを製造する方法
TWI292396B (en) Pyrimidine deriv atives
CN102321083B (zh) 一种无水盐酸莫西沙星晶型f的制备方法